Nirsevimab
Monoclonal antibody used as vaccine against RSV / From Wikipedia, the free encyclopedia
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV).[10][11] It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor[6] that is designed to bind to the fusion protein on the surface of the RSV virus.[12][13]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | F protein of RSV |
Clinical data | |
Trade names | Beyfortus |
Other names |
|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Pregnancy category |
|
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6494H10060N1708O2050S46 |
Molar mass | 146336.58 g·mol−1 |
The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given).[8][14][15]
It was developed by AstraZeneca and Sanofi.[10][11] Nirsevimab was approved for medical use in both the European Union[9][16] and the United Kingdom in November 2022,[5] in Canada in April 2023,[2][17] and in the United States in July 2023.[15] Alternatively, in October 2023 the CDC recommended maternal RSVpreF vaccination during pregnancy, though both are not needed in most infants.